Biogen Inc. (BIIB) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $192.52, but acceptable to hold if already in. Reasons: Concentration risk — Product: TYSABRI and SPINRAZA; Analyst target reached - limited upside remaining.
Biogen is a global biopharma focused on neurology (MS, Alzheimer's, ALS) and rare diseases (SMA, Friedreich's ataxia). Key marketed products include TYSABRI, SPINRAZA, SKYCLARYS, and QALSODY; LEQEMBI for Alzheimer's is co-commercialized with Eisai. TYSABRI and SPINRAZA each... Read more
Hold if already holding. Not a fresh buy at $192.52, but acceptable to hold if already in. Reasons: Concentration risk — Product: TYSABRI and SPINRAZA; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity no date, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductTYSABRI and SPINRAZA10-K Item 1: 'Product sales for TYSABRI and SPINRAZA each accounted for more than 10.0% of our total revenue for the years ended December 31, 2025, 2024 and 2023'
Material Events(8-K, last 90d)
- 2026-03-11Item 5.02MEDIUMSusan H. Alexander, Chief Legal Officer, will depart Biogen effective end of May 2026. The Company has initiated a search for the next Chief Legal Officer. No successor named at time of filing.SEC filing →
- 2026-02-11Item 5.02LOWCaroline Dorsa (Board Chair) announced she will not stand for re-election at the 2026 annual meeting. Decision not related to any disagreement. Dr. Maria C. Friere elected as Chair effective after the annual meeting.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $192.52, but acceptable to hold if already in. Reasons: Concentration risk — Product: TYSABRI and SPINRAZA; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Maintain position. Not compelling to add more. Target $192.06 (-0.2%), stop $180.18 (−6.8%), A.R:R -0.0:1. Score 5.7/10, moderate confidence.
Take-profit target: $192.06 (+0.1% upside). Target $192.06 (-0.2%), stop $180.18 (−6.8%), A.R:R -0.0:1. Stop-loss: $180.18.
Concentration risk — Product: TYSABRI and SPINRAZA; Analyst target reached - limited upside remaining.
Biogen Inc. trades at a P/E of 20.9 (forward 12.2). TrendMatrix value score: 6.0/10. Verdict: Hold.
43 analysts cover BIIB with a consensus score of 3.7/5. Average price target: $213.
What does Biogen Inc. do?Biogen is a global biopharma focused on neurology (MS, Alzheimer's, ALS) and rare diseases (SMA, Friedreich's ataxia)....
Biogen is a global biopharma focused on neurology (MS, Alzheimer's, ALS) and rare diseases (SMA, Friedreich's ataxia). Key marketed products include TYSABRI, SPINRAZA, SKYCLARYS, and QALSODY; LEQEMBI for Alzheimer's is co-commercialized with Eisai. TYSABRI and SPINRAZA each exceeded 10% of total 2025 revenue.